BeOne Medicines Says Tarlatamab Received Marketing Authorization in China for Small Cell Lung Cancer Treatment

BeOne Medicines (ONC) said Friday that China's National Medical Products Administration has given conditional marketing approval to tarlatamab for adult patients with extensive-stage small cell lung cancer, who have failed at least two prior lines of systemic chemotherapy.Approval for tarlatamab, which has been developed and commercialized in mainland China in collaboration with Amgen (AMGN), was based on two clinical trials that met their primary endpoints of tarlatamab achieving an objective response rate of 40% and a median duration of response of 9.7 months, BeOne Medicines said, according to a Google translation.Price: $314.16, Change: $+0.74, Percent Change: +0.24%

-- BeOne Medicines (ONC) said Friday that China's National Medical Products Administration has given conditional marketing approval to tarlatamab for adult patients with extensive-stage small cell lung cancer, who have failed at least two prior lines of systemic chemotherapy.

Approval for tarlatamab, which has been developed and commercialized in mainland China in collaboration with Amgen (AMGN), was based on two clinical trials that met their primary endpoints of tarlatamab achieving an objective response rate of 40% and a median duration of response of 9.7 months, BeOne Medicines said, according to a Google translation.

Price: $314.16, Change: $+0.74, Percent Change: +0.24%